Form

Cornerstone Funds File Their Annual Reports

Retrieved on: 
Friday, March 1, 2024

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Cornerstone Strategic Value Fund, Inc. (NYSE American: CLM) (CUSIP: 21924B302) and Cornerstone Total Return Fund, Inc. (NYSE American: CRF) (CUSIP: 21924U300) (individually the “Fund” or, collectively, the “Funds”) have each filed copies of their annual report on Form N-CSR with the U.S. Securities and Exchange Commission (“SEC”).

Key Points: 
  • NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Cornerstone Strategic Value Fund, Inc. (NYSE American: CLM) (CUSIP: 21924B302) and Cornerstone Total Return Fund, Inc. (NYSE American: CRF) (CUSIP: 21924U300) (individually the “Fund” or, collectively, the “Funds”) have each filed copies of their annual report on Form N-CSR with the U.S. Securities and Exchange Commission (“SEC”).
  • The annual reports are available online at www.cornerstonestrategicvaluefund.com and www.cornerstonetotalreturnfund.com .
  • Copies of these reports are also available free of charge upon request by calling 1-866-668-6558.
  • Cornerstone Advisors, LLC serves as the investment manager to the Funds.

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024

The aggregate gross proceeds from this offering are expected to be $40.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte.

Key Points: 
  • The aggregate gross proceeds from this offering are expected to be $40.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte.
  • The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions.
  • In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,010,000 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions.
  • All of the shares of common stock are being sold by Humacyte.

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024

HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.

Key Points: 
  • HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.
  • All of the shares to be sold in the offering are to be sold by Celldex.
  • In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters’ option, if any, of approximately $400.4 million, excluding underwriting discounts and commissions and other offering-related expenses.

Sage Transform 2024 Unveils Sage Copilot and Introduces Groundbreaking Tech Innovations, Product Enhancements, and Strategic Partnerships at its Flagship Event

Retrieved on: 
Friday, March 1, 2024

TORONTO, March 01, 2024 (GLOBE NEWSWIRE) --  Sage, the leader in accounting, financial, HR and payroll technology for small and mid-sized businesses (SMBs), announces several significant announcements at Sage Transform 2024, its annual conference in Las Vegas, February 26 – 29, 2024. As AI continues to transform finance and accounting, Sage is empowering customers with AI-powered solutions that solve business challenges while elevating the value of human work.

Key Points: 
  • At Sage Transform 2024, the company unveils Sage Copilot, its AI-powered productivity assistant and product enhancements to Sage Intacct.
  • Sage has also signed a strategic collaboration agreement with AWS that will help customers grow and scale their business into the future.
  • Sage Copilot automates workflows, identifies errors and generates actionable insights for businesses and accountants’ needs.
  • Sage Copilot helps with forecasting, cashflow management and generating and sending invoices with simple, natural language commands.

Plug Highlights Year of Strategic Growth and Advancements in Accelerating the Green Hydrogen Economy

Retrieved on: 
Friday, March 1, 2024

With a steadfast commitment to advancing the green hydrogen economy, the Company has achieved significant progress in revenue growth, operational efficiency, and strategic investments aimed at promoting global sustainability and energy independence.

Key Points: 
  • With a steadfast commitment to advancing the green hydrogen economy, the Company has achieved significant progress in revenue growth, operational efficiency, and strategic investments aimed at promoting global sustainability and energy independence.
  • Plug also installed a 1 MW electrolyzer system at an Amazon fulfillment center, enabling on-site green hydrogen generation for use in material handling equipment.
  • Plug also added STEF as its first European pedestal customer, providing its complete green hydrogen ecosystem across two distribution centers in France and Spain.
  • Andy Marsh, CEO of Plug, shared: "This fiscal year has marked a pivotal period in our journey towards growth and sustainability within the hydrogen economy.

Sage Transform 2024 Unveils Sage Copilot and Introduces Groundbreaking Tech Innovations, Product Enhancements, and Strategic Partnerships at its Flagship Event

Retrieved on: 
Friday, March 1, 2024

At Sage Transform 2024, the company unveils Sage Copilot, its AI-powered productivity assistant and product enhancements to Sage Intacct.

Key Points: 
  • At Sage Transform 2024, the company unveils Sage Copilot, its AI-powered productivity assistant and product enhancements to Sage Intacct.
  • Sage has also signed a strategic collaboration agreement with AWS that will help customers grow and scale their business into the future.
  • Sage Copilot automates workflows, identifies errors and generates actionable insights for businesses and accountants’ needs.
  • Sage Copilot helps with forecasting, cashflow management and generating and sending invoices with simple, natural language commands.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Instacart

Retrieved on: 
Friday, March 1, 2024

and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.

Key Points: 
  • and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Instacart’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Maison Solutions, Assertio, Dada, and Cummins and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024

For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS

Key Points: 
  • For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS
    Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Cummins class action go to: https://bespc.com/cases/CMI

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Future FinTech, AlloVir, GrafTech, and Instacart and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024

For more information on the Future FinTech class action go to: https://bespc.com/cases/FTFT

Key Points: 
  • For more information on the Future FinTech class action go to: https://bespc.com/cases/FTFT
    The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • Specifically, AlloVir said it was discontinuing the posoleucel Phase 3 studies after pre-planned analyses concluded they wouldn’t meet their primary endpoints.
  • On this news, AlloVir’s stock price fell $1.57 per share, or 67.38%, to close at $0.76 per share on December 22, 2023.
  • As of the time the complaint was filed, Instacart's common stock continues to trade below the $30.00 per share Offering price, damaging investors.

Scilex Holding Company Announces $10 Million Bought Deal Offering

Retrieved on: 
Thursday, February 29, 2024

The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions.
  • Rodman & Renshaw LLC and StockBlock Securities LLC are acting as the joint book-running managers for the offering.
  • The Company also has granted to the underwriters a 30-day option to purchase up to an additional 882,352 shares of common stock and/or Common Warrants at the public offering price, less underwriting discounts and commissions.
  • The securities described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No.